Shah Rajeev M.
SEC-identified person · CIK 1619841 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Septerna, Inc. SEPN | Director | filed 2024–2026 |
| Artiva Biotherapeutics, Inc. ARTV | Director | filed 2024–2026 |
| Silverback Therapeutics, Inc. SPRY | Director | filed 2022–2026 |
| Solid Biosciences, LLC SLDB | Director | filed 2018–2026 |
| Acrivon Therapeutics, Inc. ACRV | Director | filed 2022–2026 |
| Werewolf Therapeutics, Inc. HOWL | Director | filed 2021–2026 |
| Pepgen Inc. PEPG | Director | filed 2022–2026 |
| Sionna Therapeutics, Inc. SION | Director | filed 2025–2026 |
| Hemab Therapeutics Holdings, Inc. COAG | Director | filed 2026–2026 |
| Parabilis Medicines, Inc. PBLS | Director | filed 2026–2026 |
| Lenz Therapeutics, Inc. LENZ | Director | filed 2024–2026 |
| Vor Biopharma Inc. VOR | Director | filed 2021–2026 |
| Janux Therapeutics, Inc. JANX | Director | filed 2021–2026 |
| Nkarta, Inc. NKTX | Director | filed 2020–2026 |
| Bicara Therapeutics Inc. BCAX | Director | filed 2024–2026 |
| Eliem Therapeutics, Inc. ELYM | Director | filed 2021–2026 |
| Acumen Pharmaceuticals, Inc. ABOS | Director | filed 2021–2026 |
| Tyra Biosciences, Inc. TYRA | Director | filed 2021–2026 |
| Restorbio, Inc. TORC | Officer | filed 2026–2026 |
| Prelude Therapeutics Inc PRLD | Officer | filed 2026–2026 |
| Mineralys Therapeutics, Inc. MLYS | Director | filed 2023–2026 |
| Wave Life Sciences Ltd. WVE | Director | filed 2021–2026 |
| Evommune, Inc. EVMN | Director | filed 2025–2026 |
| Spyglass Pharma, Inc. SPG | Director | filed 2026–2026 |
| Cidara Therapeutics, Inc. CDTX | Director | filed 2024–2026 |
| Fulcrum Therapeutics, Inc. FULC | Officer | filed 2022–2025 |
| 89bio, Inc. ETNB | Director | filed 2019–2025 |
| Jade Biosciences, Inc. JBIO | Director | filed 2021–2025 |
| 4D Molecular Therapeutics, Inc. FMDT | Officer | filed 2024–2024 |
| AN2 Therapeutics, Inc. ANTX | Officer | filed 2022–2024 |
| Iteos Therapeutics, Inc. ITOS | Director | filed 2020–2024 |
| Boundless Bio, Inc. BOLD | Officer | filed 2024–2024 |
| Icosavax, Inc. ICVX | Director | filed 2021–2024 |
| Dice Therapeutics, Inc. DICE | Director | filed 2021–2023 |
| Black Diamond Therapeutics, Inc. BDTX | Director | filed 2020–2023 |
| Satsuma Pharmaceuticals, Inc. STSA | Director | filed 2019–2023 |
| Imara Inc. IMRA | Officer | filed 2020–2023 |
| Forma Therapeutics Holdings, Inc., FTMX | Director | filed 2020–2022 |
| Kala Pharmaceuticals, Inc. KALA | Director | filed 2017–2022 |
| Cytek Biosciences, Inc. CTKB | Director | filed 2021–2022 |
| Rxsight, Inc. RXST | Officer | filed 2021–2021 |
| Therapeutics Acquisition Corp. TXAC | Director | filed 2021–2021 |
| Scpharmaceuticals Inc. SCPH | Officer | filed 2020–2021 |
| Phathom Pharmaceuticals, Inc. PHAT | Officer | filed 2019–2021 |
| Orchard Therapeutics plc ORTX | Director | filed 2020–2021 |
| Iterum Therapeutics plc ITRM | Officer | filed 2020–2021 |
| Viridian Therapeutics, Inc.\DE VRDN | Officer | filed 2020–2020 |
| Rhythm Pharmaceuticals, INC. SRYTM | Officer | filed 2020–2020 |
| Vaxcyte, Inc. PCVX | Officer | filed 2020–2020 |
| Xenomics INC XNOM.PK | Officer | filed 2020–2020 |
| PMV Pharmaceuticals, Inc. PMVP | Officer | filed 2020–2020 |
| Dyne Therapeutics, Inc. DYN | Officer | filed 2020–2020 |
| TG Therapeutics, INC. TGTXD | Officer | filed 2020–2020 |
| Inhibrx, Inc. INBX | Officer | filed 2020–2020 |
| Inozyme Pharma, Inc. INZY | Officer | filed 2020–2020 |
| Pandion Therapeutics, Inc. PAND | Officer | filed 2020–2020 |
| Akouos, Inc. AKUS | Officer | filed 2020–2020 |
| Verastem, Inc. VSTM | Officer | filed 2020–2020 |
| Eidos Therapeutics, Inc. EIDX | Director | filed 2018–2020 |
| Ra Pharmaceuticals, Inc. RARX | Director | filed 2016–2020 |
| Synthorx, Inc. THOR | Officer | filed 2020–2020 |
| Kalvista Pharmaceuticals, Inc. KALV | Director | filed 2016–2017 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.